NCT00917293View on ClinicalTrials.gov

Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia

PHASE2TerminatedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2014

Conditions
Tardive Dyskinesia
Interventions
DRUG

Pyridoxal 5'-Phosphate

Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.

DRUG

Placebo

Placebo 2 pills, po bid.

Trial Locations (4)

600101

Schizophrenia Research Foundation (SCARF) Mental Health Centre, Chennai

V8R 4Z3

Vancouver Island Health Authority, Victoria

M5T 1R8

Centre for Addiction and Mental Health, Toronto

N9C 3Z4

Windsor Regional Hospital, Windsor

Sponsors

Lead Sponsor

Medicure
All Listed Sponsors
lead

Medicure

INDUSTRY

NCT00917293 - Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia | Biotech Hunter | Biotech Hunter